Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation. Avalo’s lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases.
For more information about Avalo, please visit www.avalotx.com.
Our highly targeted therapeutics have strong scientific and clinical rationale that enable accelerated clinical development and increased probability of success.
We are rapidly advancing a rich pipeline with broad clinical utility across Immunology, Immuno-oncology, and Rare Genetic Diseases.
Our focus is the development of innovative therapies in areas of high unmet need within the fields of Rare Pediatric and Orphan Diseases.
Company Details
- Employees
- 39
- Founded
- -
- Address
- 1500 Liberty Ridge Dr, Chesterbrook,pennsylvania 19087,united States
- Industry
- Biotechnology
- Website
- cerecor.com
- Keywords
- immunology.
- HQ
- Chesterbrook, Pennsylvania
Avalo Therapeutics Questions
Avalo Therapeutics's website is cerecor.com
Avalo Therapeutics's LinkedIn profile is https://www.linkedin.com/company/avalotx
Avalo Therapeutics has
39 employees.
View email and phone details for 39
employees at Avalo Therapeutics.
Avalo Therapeutics's industry is
Biotechnology
Avalo Therapeutics's top competitors are
Aeovian Pharmaceuticals,
Q32 Bio Inc.,
Dyne Therapeutics,
Cervomed,
Praxis Precision Medicines, Inc.,
Boundless Bio,
Aquestive Therapeutics,
Erasca, Inc.,
Avenzo Therapeutics,
Stoke Therapeutics.
Avalo Therapeutics's categories are Biotechnology
Avalo Therapeutics's founding year is 2011
